The effects of the angiotensin II AT 2 receptor ligands CGP 42112 and PD 123319, the AT I antagonist losartan, and the nonselective angiotensin II antagonist Sarl,IleS-angiotensin II on the upper limit of CBP auto regulation were studied in pentobarbital-anesthetized rats. Blood pressure was increased by intravenous phen ylephrine infusion, while CBP was measured continu ously from the parietal cortex by laser-Doppler flowme try. Intravenous infusions of CGP 42112 (0.1 and 1 mg kg-I min-I) and PD 123319 (0.36 and 1 mg kg-I min-I) shifted the upper limit of CBP autoregulation toward higher blood pressures without affecting baseline CBP. Sarl,IleS-angiotensin II (4 f,Lg kg-I min -I) had no effect
Angiotensin II (ANG II) is a vasoactive peptide acting as a constrictor of cerebral arteries in various models and species, both in vitro and in vivo (Ed vinsson et aI., 1993) . As exceptions, ANG II relaxes dog cerebral arteries pre contracted with prostaglan din F2a (Toda and Miyazaki, 1981; Toda, 1988) , and dilates pial arteries of rabbit and rat after topical application in vivo (Haberl et aI., 1990; 1991) . ANG II has only minimal effects on resting CBF due to the effective autoregulatory mechanisms (Hardebo et aI., 1979; Faraci et aI., 1988; Tuor et aI., 1988; Maktabi et aI., 1990; Stromberg et aI., 1993) . In a recent study ANG II, when infused in large amounts, increased CBF in rabbits by 40% (Tamaki on baseline CBP or CBP autoregulation but antagonized the effect of CGP 42112 and PD 123319. Losartan (10 mg/kg i.v. bolus) reduced baseline blood pressure and CBP and shifted the autoregulation curve toward higher blood pressures. Sarl,IleS-angiotensin II blocked the ef fect of losartan on baseline CBP but not on CBP auto regulation. These results suggest that both CGP 42112 and PD 123319 exert their effects on CBP autoregulation through stimulation of angiotensin II AT2 receptors. The mechanism by which losartan affects CBP remains un clear. Key Words: Cerebral circulation-Autoregu lation-CGP 42112-PD 123319-Losartan-Sarl,Ilesangiotensin II. et aI., 1992) . This effect may be related to the ANG II degradation product, ANG II (3-8), as implicated by Haberl et aI. (1991) .
Even if ANG II does not alter resting CBF, its cerebrovascular effects can be unmasked by study ing CBF autoregulation. Inhibition of angiotensin converting enzyme shifts the CBF autoregulatory range to lower blood pressure levels in rat (Barry et aI., 1984; Waldemar et aI., 1989) , presumably by dilatation of large cerebral arteries (Postiglione et aI., 1991) . By inference, ANG II-induced large ar tery contraction would be expected to shift the au toregulatory range to higher blood pressures, as we recently reported (Stromberg et aI., 1993) . In the same study, the autoregulatory effects of ANG II were found to be mediated by the AT 2 subtype re ceptor, in contrast to peripheral ANG II-induced vasoconstriction, which is mediated by AT 1 recep tors (Chiu et aI., 1990; Dudley et aI., 1990) . Of spe cial interest in this respect is that heretofore no other physiologic function has been assigned to the AT2 receptor, even though it is widely distributed in various tissues (Wong et aI., 1992) . Coinciding with the cerebrovascular effects of ANG II, its receptors in large cerebral arteries of the rat are exclusively of the AT2 subtype (Tsutsumi and Saavedra, 1991) .
We found earlier that the effect of PD 123319, the AT2 selective ligand (Dudley et aI., 1990) , on CBF autoregulation is consistent with an agonistic effect at AT 2 receptors because it shifted the autoregula tory curve similarly to ANG II (Stromberg et aI., 1993) . In the present study we wanted to explore further the role of AT 2 receptors on CBF autoreg ulation. To this end, we examined the effects of another selective AT2 ligand, CGP 42112 (White bread et aI., 1989) and the nonselective ANG II antagonist Sar i ,Ile 8 -ANG II (Dudley et aI., 1990) , which blocks ANG II-induced vasoconstriction of cerebral arteries (Toda and Miyazaki, 1978; Man abe et aI., 1989) .
METHODS
Male Sprague-Dawley rats (Zivic-Miller, Zelienople, PA, U.S.A.) weighing 260-400 g were anesthetized with sodium pentobarbital 60 mg/kg i.p., and additional doses were given as needed to maintain adequate anesthesia. After a tracheotomy, the rats were ventilated with room air and supplemental oxygen using an Ugo Basile 7025 Rodent Respirator (Stoelting, Wood Dale, IL, U.S.A.). Arterial blood pressure was measured with a Spectramed P23XL transducer (Spectramed, Oxnard, CA, U.S.A.) connected to a cannula inserted into the left femoral ar tery. After the animals were placed in a stereotaxic frame, the skull was exposed and a small (3 x 3 mm) hole was drilled in the parietal bone, leaving the dura mater intact. During drilling, the exposed skull was flushed with saline to prevent thermal injury. To measure cerebrocor tical blood flow, a laser-Doppler flowmetry probe (BPM 2 , Vasamedics, Inc., St. Paul, MN, U.S.A.) was fixed in a position close (�1 mm) to the dural surface. Care was taken to avoid any large vessels in the vicinity of the probe tip. The blood pressure and laser-Doppler flowm etry signals were recorded simultaneously using a Grass model 79 polygraph (Grass Instrument Co., Quincy, MA, U.S.A.). Arterial blood for blood gas analyses was drawn from the right femoral artery and analyzed with a Stat Profile 3 analyzer (Nova Biomedical, Waltham, MA, U.S.A.). The ventilation was adjusted accordingly to keep P aco2 between 35 and 40 mm Hg. Rectal tempera ture was maintained at 36.5-37SC with a heating pad.
To generate CBF autoregulation curves, blood pres sure was increased by infusing increasing amounts (0.1-10 f-Lg/min) of phenylephrine (Sigma Chemical Co., St. Louis, MO., U.S.A.) in the femoral vein or tail artery. The percent CBF, relative to baseline (100%), was plotted against the mean arterial blood pressure (MABP) (in 2.5mm Hg increments).
The The experimental drugs, except losartan, were infused continuously into the femoral veins. The infusions were started 5 min before phenylephrine. Losartan was given i. v. as a single bolus injection in a volume of 1 mllkg followed by phenylephrine infusion after 5 min. In groups f-h infusion of Sari ,Ile8-ANG II was started 5 min before CGP 42112, PD 123319, or losartan (10 min before phen ylephrine).
To examine the effect of the experimental drugs on hypocapnia-related CBF changes, rats were given saline 10 f-LI/min (n = 4), CGP 42112 1 mg kg-I min-I (n = 4), PD 123319 1 mg kg-I min-I (n = 4) and losartan 10 mg/kg (n = 4). Five minutes after starting the drug deliv ery, the rats were hyperventilated for 10 min. MABP and CBF were recorded as explained previously, and arterial blood gases were measured before and after hyperventi lation. The ratio of CBF changelP aco2 change was calcu lated.
After the experiment, the animals were killed with an i.v. bolus of saturated KCl. The experiments were carried out in accordance with the National Institutes of Health guidelines for experimental animal research.
The statistical treatment of the CBF/MABP curves in cluded two-way repeated measures analysis of variance. Baseline values and 5-min postdrug values for MABP and CBF were compared by paired t test. Baseline MABP values between experimental groups, blood gas values, and CBF/P aco2 ratios were compared with one-way anal ysis of variance and Tukey's test.
RESULTS
In all experimental groups, the effects of the given treatments on MABP and CBF were assessed before starting the phenylephrine infusion (Table 1) . When given alone, losartan was the only drug af fecting these variables. It reduced both MABP and CBF. Sar i ,Ile 8 -ANG II prevented the losartan induced CBF decrease. In all combination groups (f-h) receiving Sar i ,Ile 8 -ANG II, the MABP was lowered, even if Sar i ,Ile 8 -ANG II alone had no such effect. Because in these groups Sar i ,Ile 8 -ANG II had been infused for 10 instead of 5 min (see Meth ods), an additional three rats were examined to see whether infusion of Sar i ,Ile 8 -ANG II alone for 10 min would decrease MABP; this indeed occurred (baseline, 108 ± 2 mm Hg; 10 min, 98 ± 4 mm Hg). Therefore, the MABP decrease in groups f-h was apparently due to Sar i ,Ile 8 -ANG II. In preliminary experiments, infusion of SarI ,Ile 8 -ANG II 4 j.Lg kg-I min -I antagonized the hyperten sive effect of ANG II (0.5 j.Lg/min i.v. infusion; data not shown), confirming the blockade of the AT I re ceptors. Because the affinity of SarI ,nes-ANG II is at least as high for AT 2 as for AT I receptors (Dudley et aI., 1990) , we assumed that this dose also blocked the AT2 receptors. CGP 42112 1 mg kg-I min-I did not antagonize the hypertensive effect of ANG II (0.5 j.Lg/min i.v.), confirming that the dosages used did not block the ATI receptors. Nor did CGP 42112 increase MABP, ruling out a stimulation of the AT I receptors (Table 1) . PD 123319, when administered at doses up to 30 mg/kg, does not interfere with the AT I receptors (Dudley et aI., 1990; Stromberg et aI., 1992) . The cumulative doses of PD 123319 used in the present experiment ranged from 4 to 17 mg/ kg. Therefore, any effect of PD 123319 on ANG II receptors was most likely mediated by the AT 2 re ceptors.
The dose of phenylephrine that was needed to increase MABP was quite variable between animals and ranged from 0.2 to 2.7 j.Lg kg -I mm Hg -I. The given treatments did not modify the amount of phenylephrine required for the pressor effect. Hence, the drugs studied are not likely to interfere with phenylephrine or a-adrenergic receptors.
The upper limit of autoregulation, when calcu lated as the MABP at which mean CBF doubled, was 146 ± 12 mm Hg in the saline group. This is similar to our earlier findings in the same model (Stromberg et aI., 1993) . The analysis of the CBF/ MABP curves showed that the drug-MABP inter action was statistically significant (p < 0.01, Green- 1994 house-Geisser E-corrected value). This meant that the curves were different (i.e., not parallel). Mter this, the treatment groups were assigned by exam ination of the autoregulation curves (Figs. 1--6) to one of two groups; not different (a, b, f, g) or dif ferent (c-e, h) from control. Then the two groups thus formed were compared separately. The non significant drug-MABP interaction terms in both of these comparisons indicated that there were no sta tistical differences within these groups. In the final comparison the treatment groups within these two groups were pooled and compared with each other. This comparison gave a statistically significant drug-MABP interaction (p < 0.001) indicating that groups a, b, f, and g are different from groups c-e and h.
For the graphic presentation of the autoregulation data ( Figs. 1-6 ), all datum points were plotted with the MABP on the abscissa and the relative CBF on the ordinate. A curve was fitted through each group of datum points (treatments) by using least squares regression to a fourth order polynomial function. This curve fit was considered appropriate, since the individually fitted data from each animal gave a correlation coefficient that was generally better than 0.8 and in most cases better than 0.9. No statistical analysis of the fitted data was performed, because the drug effects were assessed by analysis of variance (see Methods).
Hyperventilation reduced CBF by 0--20%, and there were no differences between experimental groups (data not shown).
Summarizing the results, CGP 42112 dose depen- dently shifted the upper limit of CBF autoregulation toward higher blood pressures ( Fig. O. PD 123319 caused a similar shift in the autoregulation curve, but it was not as potent as CGP 42112 (Fig. 2) . Losartan also elicited a small but significant shift in the same direction, whereas Sar\Ile 8 -ANG II was not different from saline (Fig. 3) . When Sar\Ile 8 -ANG II was given together with the other treat ments, it effectively antagonized the effects of CGP 42112 ( Fig. 4) and PD 123319 ( Fig. 5 ), but not that of losartan (Fig. 6 ). e) and the nonselective ANG II antagonist Sar\lIe8-ANG II (4 flog kg-1 min-1) (---; 0) on CBF during induced hyperten sion. MABP was increased by phenylephrine infusion. los a rtan was injected and infusion of Sar1 ,lIe8-ANG II was started 5 min earlier. All obtained datum points are shown, and the curves are fitted through each group of points (n = 8) as described in Results. losartan shifts the upper limit of CBF autoregulation toward higher blood pressures, whereas
Sar\lIe8-ANG II has no effect. ---; £::' , saline. 
DISCUSSION
The effect of ANG II on CBF has been examined in several studies. In most studies, ANG II did not alter resting CBF (Greenfield and Tindall, 1968; Olesen, 1972; Tuor et aI., 1988; Maktabi et aI., 1990; Stromberg et aI., 1993) or decreased it by 12-19% (Hardebo et aI., 1979; Faraci et aI., 1988) . These results are consistent with ANG II-mediated con striction of large cerebral arteries (Edvinsson et aI., 1993) which is followed by compensatory autoreg- Sar 1 ,lIeB-ANG II did not antagonize the effect of losartan on CBF.
-; e, losartan 10 mg/kg; ---; 0, Sar1 ,lleB-ANG II 4 fL9
kg-1 min-1 + losartan 10 mg/kg. ulatory dilatation of small pial arteries and intrace rebral arterioles Edvin sson et aI., 1993) . Such an effect on the cerebral circulation is best detected by demonstrating a shift in the limits of CBF autoregulation (Paulson et aI., 1990; Edvinsson et aI., 1993) . In contrast to the above results, it was recently reported that ANG II increased CBF in rabbits when large doses were infused into the common carotid arteries (Tamaki et aI., 1992) . Because in this study the blood pressure was maintained con stant by blood withdrawal, it was suggested that the increase in CBF was mainly due to dilatation of small vessels. Haberl et ai. (1990; 1991) have of fered an explanation for ANG II-mediated dilata tion of pial arteries. When ANG II was applied top ically on the pial surface, the pial arteries were di latated apparently by the ANG II degradation product ANG II (3-8). Therefore, we believe that the cerebrovascular effects of ANG II include both large artery constriction and small artery dilatation. The latter, which is mediated by ANG II (3-8), probably requires high intravascular concentrations or topical application of ANG II. In support of the degradation hypothesis, a specific endothelial bind ing site for ANG II (3-8) was recently discovered (Swanson et aI., 1992) .
Our previous study demonstrated that ANG II shifted the upper limit of CBF autoregulation to ward higher blood pressures in the presence of the ATI antagonist losartan (Stromberg et aI., 1993) . In the same study, the AT2 ligand PD 123319 caused a similar shift in the autoregulatory curve, whereby we hypothesized that PD 123319 is an AT2 agonist. In the present study, the effect of PD 123319 was antagonized by the nonselective ANG II antagonist Sarl,Ile 8 -ANG II, which is supportive of such a hy pothesis. Furthermore, another AT 2-selective ligand, CGP 42112, shifted the autoregulatory curve even more potently than PD 123319, in accordance with binding affinities to the AT 2 receptor (White bread et aI., 1989; Dudley et aI., 1990) and its effect was also antagonized by Sarl,Ile 8 -ANG II. From these results we conclude, that ANG II elicits con traction of large cerebral arteries, shifting the auto regulatory range toward higher blood pressures, by stimulation of AT2 receptors. CGP 42112 and PD 123319 are selective agonists at this receptor. To obtain more direct evidence for our hypothesis, we have recently demonstrated that ANG II contracts the isolated rat basilar artery (unpublished observa tions).
The mechanism by which losartan causes an up ward shift in the upper limit of CBF autoregulation remains unclear. However, it is unlikely that AT I receptors are involved because Sarl,Ile 8 -ANG II did not modify the autoregulation. In addition, AT I receptors have not been found in rat cerebral arter ies. Losartan could mediate its effects indirectly through AT 2 receptors as it releases endogenous ANG II (Mizuno et aI., 1992) . This mechanism might be excluded by the present finding that the effect of losartan on autoregulation was not blocked by Sarl,Ile 8 -ANG II. On the other hand, Sarl,Ile 8 -ANG II blocked the effect of losartan on baseline CBF. Another possibility is that the effect of losartan is unrelated to angiotensin II.
We can not exclude the possibility that AT2 re ceptors in other locations besides large cerebral ar teries play a role in the observed CBF responses. It is not known whether PD 123319 and CGP 42112 cross the blood-brain barrier. However, a direct effect on cerebrocortical metabolism is unlikely be cause these compounds did not alter baseline CBF. The data regarding losartan's accessibility to the brain is controversial (Song et aI., 1991; Bui et aI., 1992) , and its effect on basal CBF (Table 1) appears to be mainly blood pressure-related. Penetration of the blood-brain barrier does not seem to be a re quirement for ANG II-induced vasoconstriction of cerebral arteries because this effect was shown to be mainly endothelium-dependent in the dog (Man abe et aI., 1989). Dog cerebral microvessels have been shown to contain ANG II receptors (Speth and Harik, 1985) , but their subtype has not been clarified. Should these receptors be located on arterioles and be of the AT2 subtype, they could play a role in the au toregulatory response. However, the preparation used by Speth and Harik (1985) contained mainly capillaries and only a small fraction of arterioles. ANG II receptors in pure arteriolar preparations have not been studied.
The hyperventilation test employed in the present experiment gave only a minimal CBF response. This was most likely due to pentobarbital-induced depression of cerebrovascular reactivity to alter ations in arterial CO2 (Edvinsson et aI. , 1993) . Any how, the response to hyperventilation was not af fected by the AT 2 agonists or losartan, suggesting that in our model these compounds had a more spe cific action on vascular adjustments in response to hypertension. This needs to be confirmed by stud ies where other means of inducing hypertension, e. g. , aortic occlusion, are used. It is obvious that a possible interaction of ANG II and arterial CO2 on cerebrovascular reactivity should be studied under nonbarbiturate anesthesia.
In conclusion, the present results offer further evidence in support of a role of ANG II AT2 recep tors in the regulation of CBF. We believe that the shift in the CBF autoregulatory limits is mediated by ANG II acting on the AT2 receptors in large cerebral arteries (Tsutsumi and Saavedra, 1991) . The finding that CGP 42112 and PD 123319 are se lective agonists at the AT 2 receptor makes them useful tools for future CBF studies. Thus, it is pos sible to study the cerebrovascular effects of ANG II without the often confounding AT 1 receptor mediated hypertensive response. 
